What Is It?
Not a SARM. Not a drug. Not even trying to be one. A REV-ERB receptor agonist research probe synthesized to study circadian rhythms. Developed by Thomas Burris at Scripps around 2012. Never intended for human use.
How Does It Work?
MK-677 wasn't a peptide. YK-11 wasn't a SARM. GW-501516 wasn't even close. SR-9009 wasn't even trying to be a drug. REV-ERB-alpha/beta agonist. One mouse endurance paper in 2012 — then the supplement industry picked it up and ran with it.
Primary Benefits (research suggests)
- Mouse endurance improvements in one 2012 study
- That's it — the entire commercial market is built on one animal paper
Run the Numbers
Calculate your SR-9009 dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- Oral bioavailability is approximately 2-3%, with a half-life of just a few hours.
- Almost none reaches the bloodstream when taken orally — so users inject it instead.
- Zero human trials.
- Off-target mechanism effects unknown.
- Often stacked with GW-501516 (the compound with cancer evidence).
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track SR-9009 in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →